Ohio Board of Pharmacy BANS sale of hydroxychloroquine to treat coronavirus as Yale epidemiologist says hydroxychloroquine is ‘the key to defeating COVID-19’

The 100 year old drug works.

This is frightening. The left is weaponizing treatment.

Yale epidemiologist says hydroxychloroquine is ‘the key to defeating COVID-19’

American Doctors Address COVID-19 Misinformation with SCOTUS Press Conference

Ohio Board of Pharmacy bans sale of hydroxychloroquine to treat coronavirus

By: WCMH,  Jul 29, 2020:

COLUMBUS, Ohio (WCMH) — Beginning July 30, an Ohio Board of Pharmacy rule goes into effect banning the dispensing of hydroxychloroquine for the treatment or prevention of COVID-19.

The rule prohibits pharmacies from selling or dispensing hydroxychloroquine and chloroquine for use as a coronavirus treatment without approval from the board’s executive director. It also specifies that all prior approvals for the drugs are no longer applicable.

The rule does not apply to board-approved clinical trials. Participants must have documentation that they are part of such a trial. It does not apply to prescriptions to treat other conditions.

The rule reads:

4729:5-5-21 Prescription requirements for chloroquine and hydroxychloroquine.

(A) No prescription for chloroquine or hydroxychloroquine may be dispensed by a
pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs, including
prescriptions for patients residing in Ohio dispensed or sold at retail by nonresident terminal
distributors of dangerous drugs as defined in rule 4729:5-8-01 of the Administrative Code,
unless the prescription bears a written diagnosis code from the prescriber or a statement
indicating its veterinary medical purpose.

(B) Except as provided in paragraph (C) of this rule, prescriptions issued for chloroquine or
hydroxychloroquine for prophylactic use related to COVID-19 or for the treatment of COVID19 are strictly prohibited unless otherwise approved by the board’s executive director in
consultation with the board president, at which time a resolution shall issue. Upon the
effective date of this rule, all previous approvals for the use of chloroquine or
hydroxychloroquine shall be deemed void and must be approved using the process outlined
in this paragraph.

(C) The prohibition in paragraph (B) of this rule does not apply to prescriptions issued as
part of a documented institutional review board-approved clinical trial to evaluate the safety
and efficacy of the drugs to treat COVID-19. Prescriptions must include documentation that
the patient is enrolled in a clinical trial.

(D) Paragraphs (B) and (C) of this rule shall also apply to medication orders and outpatient
prescriptions dispensed by institutional pharmacies as defined in agency 4729 of the
Administrative Code.